<![CDATA[ SUMITOMO PHARMA Co., Ltd. : News Releases ]]> https://www.sumitomo-pharma.com/news/ en © 2005-2026 Sumitomo Pharma Co., Ltd. Wed, 12 Aug 26 16:53:24 +0900 <![CDATA[ SUMITOMO PHARMA Co., Ltd. ]]> https://www.sumitomo-pharma.com/ https://www.sumitomo-pharma.com/assets/img/img-ogp-01.webp 4765 <![CDATA[ Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ene20260813_1.pdf R&D/Press Releases/IR News Thu, 13 Aug 26 08:30:00 +0900 4761 <![CDATA[ Regarding a Report Concerning Sumitomo Pharma (The Company's Views on “Sumitomo Chemical and Sumitomo Pharmaceutical: Part II - CiRA, Dr. Yamanaka, and the undisclosed history of image duplication concerns”) ]]> https://www.sumitomo-pharma.com/news/20260812-1.html Others/Press Releases/IR News Wed, 12 Aug 26 08:30:00 +0900 4755 <![CDATA[ Additional Explanation Regarding the Report “Sumitomo Chemical and Sumitomo Pharmaceutical: The ¥116 billion Swiss Shuffle” ]]> https://www.sumitomo-pharma.com/news/20260807-1.html Others/Press Releases/IR News Fri, 07 Aug 26 12:55:17 +0900 4752 <![CDATA[ Sumitomo Pharma Contributes to Relief Efforts for the 2026 Kumamoto Earthquake ]]> https://www.sumitomo-pharma.com/news/20260804-2.html Others/Press Releases/IR News Tue, 04 Aug 26 15:00:00 +0900 4748 <![CDATA[ Regarding a Report Concerning Sumitomo Pharma ]]> https://www.sumitomo-pharma.com/news/20260804-1.html Others/Press Releases/IR News Tue, 04 Aug 26 14:00:00 +0900 4743 <![CDATA[ Posted Conference on Q1 FY2026 Financial Results [Webcast] ]]> https://www.sumitomo-pharma.com/ir/library/presentation/ Finances/Press Releases/IR News Mon, 03 Aug 26 20:00:00 +0900 4741 <![CDATA[ Sumitomo Pharma Announces Personnel Change ]]> https://www.sumitomo-pharma.com/news/20260803-1.html Corporate/Press Releases/IR News Mon, 03 Aug 26 10:00:00 +0900 4733 <![CDATA[ Presentation Material (Conference on Q1 FY2026 Financial Results ) ]]> https://www.sumitomo-pharma.com/news/assets/pdf/eir20260731.pdf Finances/Press Releases/IR News Fri, 31 Jul 26 15:30:30 +0900 4732 <![CDATA[ Supplementary Financial Data (IFRS) for the Three Months Ended June 30, 2026 ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ebr20260731_2.pdf Finances/Press Releases/IR News Fri, 31 Jul 26 15:30:20 +0900 4731 <![CDATA[ Summary of Consolidated Financial Results for the Three Months Ended June 30, 2026 [IFRS] ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ebr20260731_1.pdf Finances/Press Releases/IR News Fri, 31 Jul 26 15:30:10 +0900 4726 <![CDATA[ Development of the Regenerative Medicine Product “AMCHEPRY” Receives the 10th Japan Bioindustry Award ]]> https://www.sumitomo-pharma.com/news/20260715.html Products/Press Releases/IR News Wed, 15 Jul 26 14:30:00 +0900 4711 <![CDATA[ Consolidated Financial Statements for Years ended March 31, 2026 and 2025 ]]> https://www.sumitomo-pharma.com/ir/library/financial_results_summary/ Finances/IR News/Notices Tue, 30 Jun 26 12:00:00 +0900 4716 <![CDATA[ Matters Concerning Controlling Shareholders, Etc. ]]> https://www.sumitomo-pharma.com/news/20260625.html Corporate/Press Releases/IR News Thu, 25 Jun 26 15:30:00 +0900 4702 <![CDATA[ Wegovy Subcutaneous Injection, Co-Promoted with Novo Nordisk Pharma, Approved in Japan for Metabolic Dysfunction-Associated Steatohepatitis (MASH) ]]> https://www.sumitomo-pharma.com/news/20260619.html Products/Press Releases/IR News Fri, 19 Jun 26 14:00:00 +0900 4698 <![CDATA[ Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ene20260616.pdf R&D/Press Releases/IR News Tue, 16 Jun 26 08:30:00 +0900 4688 <![CDATA[ Update on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemia ]]> https://www.sumitomo-pharma.com/news/20260610.html R&D/Press Releases/IR News Wed, 10 Jun 26 11:30:00 +0900 4684 <![CDATA[ Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026 ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ene20260602.pdf R&D/Press Releases/IR News Tue, 02 Jun 26 08:30:00 +0900 4681 <![CDATA[ Sumitomo Pharma Announces Organizational Change, Change in the Responsibilities of Executive Officer, and Personnel Change ]]> https://www.sumitomo-pharma.com/news/20260601.html Corporate/Press Releases/IR News Mon, 01 Jun 26 10:30:00 +0900 4678 <![CDATA[ Posted Notice of Convocation of the 206th Annual Shareholders' Meeting ]]> https://www.sumitomo-pharma.com/ir/shareholder/shareholder.html Corporate/Notices/IR News Fri, 29 May 26 09:00:00 +0900 4670 <![CDATA[ Notice Regarding Results of Capital Increase by way of Third-Party Allotment (Not Implemented) ]]> https://www.sumitomo-pharma.com/news/20260522.html Finances/Press Releases/IR News Fri, 22 May 26 16:40:00 +0900 4667 <![CDATA[ Posted Conference on FY2025 Financial Results [Webcast] ]]> https://www.sumitomo-pharma.com/ir/library/presentation/ Finances/Press Releases/IR News Fri, 15 May 26 20:12:00 +0900 4661 <![CDATA[ Presentation Material (Conference on FY2025​ Financial Results ) ]]> https://www.sumitomo-pharma.com/news/assets/pdf/eir20260513.pdf Finances/Press Releases/IR News Wed, 13 May 26 13:00:40 +0900 4659 <![CDATA[ Supplementary Financial Data (IFRS) for the Year Ended March 31, 2026 ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ebr20260513_2.pdf Finances/Press Releases/IR News Wed, 13 May 26 13:00:30 +0900 4658 <![CDATA[ Summary of Consolidated Financial Results for the Year Ended March 31, 2026 [IFRS] ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ebr20260513_1.pdf Finances/Press Releases/IR News Wed, 13 May 26 13:00:20 +0900 4655 <![CDATA[ Sumitomo Pharma Announces Personnel Changes ]]> https://www.sumitomo-pharma.com/news/20260513-1.html Corporate/Press Releases/IR News Wed, 13 May 26 13:00:10 +0900 4647 <![CDATA[ Notice regarding Withdrawal of Shelf Registration Statement for Issuance of New Shares ]]> https://www.sumitomo-pharma.com/news/20260427.html Finances/Press Releases/IR News Mon, 27 Apr 26 11:30:00 +0900 4638 <![CDATA[ Notice Regarding Determination of Issue Price, Selling Price and Other Matters ]]> https://www.sumitomo-pharma.com/news/20260420-1.html Finances/Press Releases/IR News Mon, 20 Apr 26 17:30:00 +0900 4629 <![CDATA[ Notice Regarding Issuance of New Shares and Secondary Offering of Shares ]]> https://www.sumitomo-pharma.com/news/20260408-2.html Finances/Press Releases/IR News Wed, 08 Apr 26 16:00:10 +0900 4626 <![CDATA[ Notice Regarding Refinancing of Existing Borrowings through a Bridge Loan ]]> https://www.sumitomo-pharma.com/news/20260408-1.html Finances/Press Releases/IR News Wed, 08 Apr 26 16:00:00 +0900 4621 <![CDATA[ Sumitomo Pharma Submits Partial Change Application in Japan to Add Pediatric Dosage and Administration for LATUDA in Schizophrenia ]]> https://www.sumitomo-pharma.com/news/20260330.html R&D/Press Releases/IR News Mon, 30 Mar 26 15:30:00 +0900 4617 <![CDATA[ Notice Concerning Non-operating Income Recorded in the Company’s Non-consolidated Financial Statements (Japanese GAAP) ]]> https://www.sumitomo-pharma.com/news/20260325.html Finances/Press Releases/IR News Wed, 25 Mar 26 15:30:00 +0900 4595 <![CDATA[ Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY” in Japan ]]> https://www.sumitomo-pharma.com/news/20260306.html Products/Press Releases/IR News Fri, 06 Mar 26 09:00:00 +0900 4593 <![CDATA[ Posted Conference on Boost 2028 - Accelerating Strong Sumitomo Pharma - [Webcast] ]]> https://www.sumitomo-pharma.com/ir/library/presentation/ Finances/Press Releases/IR News Wed, 04 Mar 26 16:00:00 +0900 4580 <![CDATA[ Sumitomo Pharma Announces Organizational Realignment and Changes in Executive Officers and Other Key Positions ]]> https://www.sumitomo-pharma.com/news/20260303.html Corporate/Press Releases/IR News Tue, 03 Mar 26 10:00:00 +0900 4566 <![CDATA[ Presentation Material (Boost 2028 - Accelerating Strong Sumitomo Pharma -) ]]> https://www.sumitomo-pharma.com/news/assets/pdf/eir20260302.pdf Finances/Press Releases/IR News Mon, 02 Mar 26 15:30:40 +0900 4564 <![CDATA[ Announcement of Filing of Shelf Registration Statement for Issuance of New Shares ]]> https://www.sumitomo-pharma.com/news/20260302-3.html Finances/Press Releases/IR News Mon, 02 Mar 26 15:30:30 +0900 4562 <![CDATA[ Sumitomo Pharma Announces Boost 2028 - Accelerating Strong Sumitomo Pharma - ]]> https://www.sumitomo-pharma.com/news/20260302-2.html Finances/Press Releases/IR News Mon, 02 Mar 26 15:30:20 +0900 4560 <![CDATA[ Sumitomo Pharma Announces Revisions to Its Financial Forecasts ]]> https://www.sumitomo-pharma.com/news/20260302-1.html Finances/Press Releases/IR News Mon, 02 Mar 26 15:30:10 +0900 4558 <![CDATA[ Interim Analysis (Cross‑Reactivity) of Phase 1 Clinical Study in Europe on Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546) ]]> https://www.sumitomo-pharma.com/news/20260226-2.html R&D/Press Releases/IR News Thu, 26 Feb 26 15:30:10 +0900 4549 <![CDATA[ Termination of License Agreement for Selective Orexin 2 Receptor Agonist DSP‑0187 ]]> https://www.sumitomo-pharma.com/news/20260226-1.html Licensing/Press Releases/IR News Thu, 26 Feb 26 15:30:00 +0900 4540 <![CDATA[ Launch of Joint Research on a Novel Multi-Stage Malaria Vaccine by Ehime University and Sumitomo Pharma and Grant Award from the GHIT Fund ]]> https://www.sumitomo-pharma.com/news/20260220.html R&D/Press Releases/IR News Fri, 20 Feb 26 14:00:00 +0900 4537 <![CDATA[ Posted R&D Meeting [Webcast] ]]> https://www.sumitomo-pharma.com/ir/library/presentation/ R&D/Press Releases/IR News Thu, 19 Feb 26 14:32:50 +0900 4531 <![CDATA[ Posted Presentation Material (R&D Meeting) ]]> https://www.sumitomo-pharma.com/news/assets/pdf/eir20260217.pdf R&D/Press Releases/IR News Tue, 17 Feb 26 13:00:00 +0900 4529 <![CDATA[ Regarding the Scheduled Review in Japan of the Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells (AMCHEPRY) ]]> https://www.sumitomo-pharma.com/news/20260213.html Products/Press Releases/IR News Fri, 13 Feb 26 17:20:00 +0900 4464 <![CDATA[ Posted Conference on Q3 FY2025 Financial Results [Webcast] ]]> https://www.sumitomo-pharma.com/ir/library/presentation/ Finances/Press Releases/IR News Mon, 02 Feb 26 15:12:00 +0900 4432 <![CDATA[ Presentation Material (Conference on Q3 FY2025 Financial Results) ]]> https://www.sumitomo-pharma.com/news/assets/pdf/eir20260130.pdf Finances/Press Releases/IR News Fri, 30 Jan 26 15:30:30 +0900 4431 <![CDATA[ Supplementary Financial Data (IFRS) for the Third Quarte of the Year Ending March 31, 2026 ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ebr20260130_2.pdf Finances/Press Releases/IR News Fri, 30 Jan 26 15:30:20 +0900 4430 <![CDATA[ Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2025 [IFRS] ]]> https://www.sumitomo-pharma.com/news/assets/pdf/ebr20260130_1.pdf Finances/Press Releases/IR News Fri, 30 Jan 26 15:30:10 +0900 4425 <![CDATA[ Sumitomo Pharma Selected as “Best Website” for the Third Consecutive Year in Both All Markets and Pharmaceuticals Sector Categories of Nikko Investor Relations’ FY2025 All-Listed-Companies Website Ranking ]]> https://www.sumitomo-pharma.com/news/20251222.html Others/Press Releases/IR News Mon, 22 Dec 25 11:30:00 +0900 4415 <![CDATA[ Sumitomo Pharma Selected as Highest Rating A-List Company by CDP for Two Consecutive Years in the Category of Climate Change in the CDP 2025 ]]> https://www.sumitomo-pharma.com/news/20251215.html Sustainability/Press Releases/IR News Mon, 15 Dec 25 11:00:00 +0900